Your browser is no longer supported. Please, upgrade your browser.
CRSP CRISPR Therapeutics AG daily Stock Chart
CRSP [NASD]
CRISPR Therapeutics AG
Index- P/E- EPS (ttm)-0.32 Insider Own3.10% Shs Outstand46.43M Perf Week18.34%
Market Cap1.57B Forward P/E- EPS next Y-2.85 Insider Trans-49.18% Shs Float28.88M Perf Month76.70%
Income-51.40M PEG- EPS next Q-0.69 Inst Own38.40% Short Float5.05% Perf Quarter77.91%
Sales11.00M P/S142.46 EPS this Y-194.70% Inst Trans0.21% Short Ratio3.05 Perf Half Y102.82%
Book/sh4.46 P/B7.57 EPS next Y-17.80% ROA-16.40% Target Price27.33 Perf Year68.75%
Cash/sh5.46 P/C6.18 EPS next 5Y- ROE-24.90% 52W Range11.63 - 34.18 Perf YTD43.74%
Dividend- P/FCF- EPS past 5Y- ROI-24.50% 52W High12.35% Beta-
Dividend %- Quick Ratio21.30 Sales past 5Y- Gross Margin- 52W Low230.18% ATR2.24
Employees93 Current Ratio21.30 Sales Q/Q60.00% Oper. Margin- RSI (14)83.65 Volatility9.38% 8.85%
OptionableYes Debt/Eq0.00 EPS Q/Q-66.90% Profit Margin- Rel Volume5.01 Prev Close33.75
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume478.96K Price38.40
Recom2.30 SMA2050.41% SMA5079.35% SMA200107.54% Volume1,956,920 Change13.78%
Jan-23-18Upgrade SunTrust Hold → Buy
Dec-22-17Initiated Piper Jaffray Overweight
Jul-14-17Initiated SunTrust Hold $16
Mar-28-17Initiated Chardan Capital Markets Buy $23.50
Jan-23-18 12:57PM  Here's What's Driving Crispr Therapeutics AG Higher Today Motley Fool +13.78%
05:20AM  Chinese scientists used Crispr gene editing on 86 human patients Quartz
Jan-22-18 12:45AM  [$$] China, Unhampered by Rules, Races Ahead in Gene-Editing Trials The Wall Street Journal +13.52%
Jan-16-18 07:34AM  CRISPR Gene-Editing Stocks Going Down the Tubes? Think Again Motley Fool
Jan-09-18 06:09AM  10 Things to Expect From Vertex Pharmaceuticals in 2018 Motley Fool
Jan-08-18 08:46AM  CRISPR Therapeutics (CRSP) Jumps: Stock Rises 12.1% Zacks
08:00AM  Uh-Oh! CRISPR Gene-Editing Stocks May Be Worthless Motley Fool
03:00AM  Stocks Showing Market Leadership: CRISPR Therapeutics Earns 92 RS Rating Investor's Business Daily
Jan-05-18 01:48PM  Why CRISPR Therapeutics AG Stock Is Rising Today Motley Fool +12.13%
12:10PM  Investors Cheer Secondary Offering for Gene-Editing Firm 24/7 Wall St.
Jan-04-18 07:03PM  CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares GlobeNewswire
04:36PM  Here's Why Intellia Therapeutics Inc. Fell 14.7% in December Motley Fool
10:47AM  Here's What Pushed Crispr Therapeutics AG Up 23.6% in December Motley Fool
Jan-03-18 06:15AM  CRISPR Therapeutics Announces Proposed Public Offering of Common Shares GlobeNewswire -6.56%
Dec-27-17 01:24PM  [$$] Celgene: Two Small-Cap Biotech Stocks It's Selling Barrons.com
08:55AM  CRISPR Therapeutics AG :CRSP-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Dec-22-17 12:32PM  CRISPR Therapeutics Stock Wins a Buy Rating: What You Need to Know Motley Fool +8.02%
Dec-21-17 08:00AM  CRISPR Therapeutics Announces Appointment of Dr. Rodger Novak as Chairman of the Board GlobeNewswire
Dec-12-17 08:30AM  Vertex and CRISPR Therapeutics to Co-Develop and Co-Commercialize CTX001 as CRISPR/Cas9 Gene Edited Treatment for Sickle Cell Disease and -Thalassemia Business Wire
Dec-10-17 09:25PM  Cambridge biotechs among big winners at ASH blood disease conference American City Business Journals
07:45AM  CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Therapy for -Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting GlobeNewswire
Dec-07-17 07:00AM  CRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy, CTX001 in -thalassemia GlobeNewswire
Dec-05-17 08:00AM  CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Medicine for -Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting GlobeNewswire
07:47AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : December 5, 2017 Capital Cube
Nov-29-17 08:26PM  Bitcoin or CRISPR: Which is the Bigger Disruptor? Zacks
Nov-28-17 08:00AM  CRISPR Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-22-17 01:15PM  FDA warns against do it yourself gene therapy kits American City Business Journals
Nov-21-17 07:33AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bullish Manner : CRSP-US : November 21, 2017 Capital Cube
Nov-14-17 07:34AM  Disruptor Alert: These 5 Companies Are Changing Healthcare Motley Fool
Nov-13-17 11:20AM  MIT scientists deploy new CRISPR delivery system to edit genes in mice American City Business Journals
08:00AM  CRISPR Therapeutics Announces Appointment of Michael Tomsicek as Chief Financial Officer GlobeNewswire
05:00AM  CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs GlobeNewswire
Nov-10-17 08:00PM  CRISPR Therapeutics Highlights New Additions to Portfolio of Allogeneic CRISPR-based CAR-T Therapies at SITC Annual Meeting GlobeNewswire
Nov-08-17 04:05PM  CRISPR Therapeutics Announces Third Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Nov-07-17 03:48PM  Editas CEO to testify at U.S. Senate hearing on gene editing potential, ethics American City Business Journals
11:40AM  Why CRISPR Therapeutics AG Stock Edged Higher in October Motley Fool
08:00AM  CRISPR Therapeutics to Present New Data on Allogeneic CRISPR-based CAR-T Program and Host Investor Reception at the 32nd Annual Society for Immunotherapy of Cancer Meeting GlobeNewswire
07:04AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bullish Manner : CRSP-US : November 7, 2017 Capital Cube
Oct-30-17 12:38PM  CRISPR Therapeutics AG Value Analysis (NASDAQ:CRSP) : October 30, 2017 Capital Cube
Oct-27-17 08:29AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : October 27, 2017 Capital Cube
Oct-13-17 08:30AM  CRISPR Therapeutics Awarded Grant from Friedreichs Ataxia Research Alliance to Collaborate with University of Alabama at Birmingham on Gene-edited Treatments for Friedrichs Ataxia GlobeNewswire
Oct-12-17 08:24AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : October 12, 2017 Capital Cube
Oct-10-17 10:00AM  Why CRISPR Therapeutics AG Stock Lost Ground in September Motley Fool
Oct-04-17 04:01PM  CRISPR Therapeutics to Present at Investor Conferences in October GlobeNewswire
Oct-02-17 07:30AM  CRISPR Therapeutics Announces Promotion of Samarth Kulkarni, Ph.D. to Chief Executive Officer GlobeNewswire
Sep-27-17 08:17AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : September 27, 2017 Capital Cube
Sep-18-17 12:38PM  CRISPR Therapeutics AG :CRSP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 Capital Cube
Sep-07-17 03:32PM  Breaking Down Barclays' New Bullish Calls On Biotech Benzinga
Aug-31-17 11:29AM  How a CRISPR, gene-editing technology, patent ruling could move stocks Harvest Exchange
Aug-24-17 10:50AM  CRISPR Therapeutics, MGH team up on new cancer treatments American City Business Journals +5.11%
Aug-22-17 07:30AM  CRISPR Therapeutics Announces Collaboration with Massachusetts General Hospital to Research Use of CRISPR/Cas9 in T Cell Cancer Therapies GlobeNewswire
Aug-13-17 11:01AM  This Technology Could Make You Rich -- and Change the World As We Know It Motley Fool
Aug-10-17 04:35PM  CRISPR Therapeutics Announces Second Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Aug-01-17 07:00AM  CRISPR Therapeutics Appoints Dr. Tony W. Ho to Head Research & Development GlobeNewswire
Jul-25-17 05:00PM  CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing GlobeNewswire
Jul-17-17 07:06AM  This Is Why Investors Will Need to Learn a New Acronym: CRISPR Motley Fool
Jul-15-17 03:40PM  Never Will I Ever Buy Preclinical Biotech Stocks. No Way! Motley Fool
12:03PM  Why You're Smart to Buy Vertex Pharmaceuticals Stock Motley Fool
Jul-10-17 12:35PM  Why CRISPR Therapeutics AG Jumped 11.7% in June Motley Fool
08:30AM  CRISPR Therapeutics and Neon Therapeutics Enter Research Collaboration GlobeNewswire
08:00AM  CRISPR Gene Editing Controversy: Does It Really Cause Unexpected Mutations? Forbes
Jul-09-17 06:02AM  3 Growth Stocks for Forward-Looking Investors Motley Fool
Jul-05-17 04:30PM  CRISPR Therapeutics to Present at the Piper Jaffray GenomeRx Symposium GlobeNewswire
Jun-23-17 08:14AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bullish Manner : CRSP-US : June 23, 2017 Capital Cube
Jun-19-17 07:30AM  CRISPR Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China GlobeNewswire
Jun-14-17 08:30AM  CRISPR Therapeutics to Present at the JMP Securities Life Sciences Conference GlobeNewswire
Jun-07-17 08:30AM  CRISPR Therapeutics Appoints James R. Kasinger as General Counsel GlobeNewswire
Jun-06-17 03:20PM  Two gene editing firms unveil cancer drug pacts as ASCO comes to a close American City Business Journals
08:30AM  CRISPR Therapeutics and MaSTherCell SA sign service agreement for the development and manufacturing of allogeneic cell therapies GlobeNewswire
Jun-02-17 09:58AM  CRISPR Therapeutics AG :CRSP-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
May-30-17 04:17PM  Here's Why Editas Medicine Fell as Much as 15.7% Today Motley Fool -5.32%
May-18-17 08:30AM  CRISPR Therapeutics Announces the Presentation of Data on its Lead Program at the Upcoming 22nd European Hematology Association Annual Congress GlobeNewswire
May-16-17 08:00AM  CRISPR Therapeutics and collaborators at the University of Florida awarded Target ALS Grant to develop CRISPR/Cas9-based approaches for ALS GlobeNewswire
May-12-17 04:50PM  CRISPR Therapeutics to Present at Investor Conferences in May GlobeNewswire
May-11-17 08:30AM  CRISPR Therapeutics Reports Financial Results for the Three Months Ended March 31, 2017 and Provides Business Update GlobeNewswire
May-08-17 02:45PM  Cambridge gene editing firm CRISPR to use delivery tech honed at MIT American City Business Journals
08:00AM  CRISPR Therapeutics Announces Exclusive License of Lipid Nanoparticle Technologies Developed at MIT GlobeNewswire
May-04-17 08:00AM  CRISPR Therapeutics Appoints Samarth Kulkarni, Ph.D. as President, Expanding Role Beyond Chief Business Officer To Oversee U.S. Operations GlobeNewswire
Apr-27-17 08:00AM  CRISPR Therapeutics to Present at the 42nd Annual Deutsche Bank Health Care Conference GlobeNewswire
Apr-26-17 07:30AM  Intellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein Complexes GlobeNewswire
Apr-17-17 08:00AM  CRISPR Therapeutics and Casebia Therapeutics Announce Exclusive Development and Option Agreement with StrideBio GlobeNewswire
Apr-13-17 07:30AM  CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board Decision GlobeNewswire
Apr-11-17 08:41AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : April 11, 2017 Capital Cube
Mar-31-17 04:33PM  CRISPR THERAPEUTICS AG Files SEC form 8-K, Other Events, Financial Statements and Exhibits +5.07%
Mar-30-17 08:00AM  CRISPR Therapeutics to Present at the 16th Annual Needham Healthcare Conference GlobeNewswire
Mar-28-17 08:00AM  CRISPR Therapeutics Announces European Patent for CRISPR/Cas Gene Editing GlobeNewswire +11.95%
06:08AM  Coverage initiated on CRISPR Therapeutics by Chardan Capital Markets
Mar-23-17 08:14AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : March 23, 2017 Capital Cube
08:14AM  CRISPR Therapeutics AG breached its 50 day moving average in a Bearish Manner : CRSP-US : March 23, 2017
Mar-20-17 04:33PM  CRISPR THERAPEUTICS AG Files SEC form 8-K, Change in Directors or Principal Officers
10:23AM  CRISPR Therapeutics AG :CRSP-US: Earnings Analysis: 2016 By the Numbers : March 20, 2017 Capital Cube
10:23AM  CRISPR Therapeutics AG :CRSP-US: Earnings Analysis: 2016 By the Numbers : March 20, 2017
Mar-16-17 02:12PM  [$$] EGenesis Raises $38 Million Series A, Targets Organ Shortage The Wall Street Journal
02:12PM  [$$] EGenesis Raises $38 Million Series A, Targets Organ Shortage at The Wall Street Journal
Mar-14-17 03:55PM  CRISPR to Use MaxCyte Cell Engineering Platform Investopedia
03:55PM  CRISPR to Use MaxCyte Cell Engineering Platform at Investopedia
07:00AM  CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement With MaxCyte GlobeNewswire
Mar-10-17 04:23PM  CRISPR Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update GlobeNewswire
04:15PM  CRISPR THERAPEUTICS AG Files SEC form 10-K, Annual Report
Mar-02-17 04:30PM  CRISPR Therapeutics to Present at the Annual Barclays Global Healthcare Conference GlobeNewswire
CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The CRISPR/Cas9 technology allows for changes to genomic DNA. The company has strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases. It operates in Switzerland, the United States, and the United Kingdom. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CELGENE CORP /DE/10% OwnerNov 21Sale19.2580,0001,540,0004,173,019Dec 07 09:57 AM
Dylan-Hyde TylerChief Legal OfficerJan 16Option Exercise12.5721,000263,97045,094Jan 18 05:38 PM
Dylan-Hyde TylerChief Legal OfficerJan 16Sale28.0366,0001,850,25525,204Jan 18 05:38 PM
EMSTER KURT VONDirectorJan 05Buy22.7565,9341,499,9991,887,202Jan 11 09:00 PM
EMSTER KURT VONDirectorJan 05Sale26.9692,3372,489,4061,821,268Jan 09 04:39 PM
Dylan-Hyde TylerChief Legal OfficerJan 02Option Exercise12.578,000100,56078,204Jan 04 07:14 PM
Dylan-Hyde TylerChief Legal OfficerJan 02Sale21.6438,000822,50070,204Jan 04 07:14 PM
EMSTER KURT VONDirectorJan 02Sale26.7637,7541,010,1231,913,605Jan 04 05:29 PM
Dylan-Hyde TylerChief Legal OfficerDec 29Option Exercise13.3315,300203,909124,274Jan 02 04:18 PM
Dylan-Hyde TylerChief Legal OfficerDec 29Sale22.7430,300689,055100,204Jan 02 04:18 PM
Dylan-Hyde TylerChief Legal OfficerDec 28Option Exercise14.4370010,101115,904Jan 02 04:18 PM
Dylan-Hyde TylerChief Legal OfficerDec 28Sale21.7570015,225115,204Jan 02 04:18 PM
Bolzon Bradley J PhDDirectorDec 22Sale20.3026,016528,23727,724Dec 27 04:17 PM
Dylan-Hyde TylerChief Legal OfficerDec 22Sale20.5515,000308,250115,204Dec 27 04:17 PM
Woiwode ThomasDirectorDec 22Sale20.293,05962,0704,959Dec 27 04:14 PM
Kulkarni SamarthChief Executive OfficerDec 21Option Exercise1.8115,00027,150148,560Dec 26 05:11 PM
Dylan-Hyde TylerChief Legal OfficerDec 15Sale18.9015,000283,496130,204Dec 19 04:10 PM
CELGENE CORP /DE/10% OwnerDec 04Sale19.4730,485593,5433,722,534Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerDec 01Sale19.1087,9911,680,6283,753,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 30Sale19.0412,666241,1613,841,010Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 29Sale19.254,26382,0633,853,676Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 28Sale19.225,08097,6383,857,939Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 27Sale19.7527,990552,8033,863,019Dec 07 09:57 AM
Bolzon Bradley J PhDDirectorNov 27Sale20.242004,04853,740Nov 28 04:10 PM
Woiwode ThomasDirectorNov 27Sale20.242004,0488,018Nov 28 04:11 PM
Woiwode ThomasDirectorNov 24Sale20.211,70034,3588,218Nov 28 04:11 PM
Bolzon Bradley J PhDDirectorNov 24Sale20.211,50730,45053,940Nov 28 04:10 PM
CELGENE CORP /DE/10% OwnerNov 24Sale20.0026,010520,2003,891,009Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 22Sale19.76256,0005,058,5603,917,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 20Sale19.02158,7183,018,8164,253,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 17Sale18.4451,282945,6404,411,737Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 16Sale18.39105,0001,930,9504,463,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 15Sale17.6715,000265,0504,568,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 14Sale17.1914,907256,2514,583,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 13Sale17.7665,0931,156,0524,597,926Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 10Sale17.2810,000172,8004,663,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 09Sale17.0820,000341,6004,673,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 08Sale18.0616,875304,7634,693,019Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 07Sale18.5423,000426,4204,709,894Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 06Sale18.8979,3271,498,4874,732,894Dec 07 09:57 AM
CELGENE CORP /DE/10% OwnerNov 03Sale19.1022,759434,6974,812,221Dec 07 09:57 AM
Novak RodgerChief Executive OfficerSep 05Option Exercise1.813,8536,9741,151,860Sep 05 06:33 PM
Novak RodgerChief Executive OfficerSep 05Sale20.333,85378,3201,148,007Sep 05 06:33 PM
Novak RodgerChief Executive OfficerAug 31Sale20.8714,617305,0731,148,007Sep 05 06:33 PM